Psoriatic Arthritis
Psoriatic arthritis (PsA) is a long-lasting condition that causes inflammation in the joints and skin for those with psoriasis (PsO). This study aims to see how well a new treatment works for people with active PsA who haven't used certain other medications before.
Study site: NeoClinical Research
- Psoriatic arthritis (PsA)
- About the Study
- Psoriatic arthritis (PsA) is a long-lasting condition that causes inflammation in the joints and skin for those with psoriasis (PsO). This study aims to see how well a new treatment works for people with active PsA who haven't used certain other medications before. Participants will receive either the new treatment, a comparison treatment, or a placebo (a non-active pill) for up to 60 weeks.
- What does the study involve?
- Participants will take either over-encapsulated tablets of the new treatment, a comparison capsule, or a matching placebo.
What to expect
- Placebo
- You may receive a placebo (a look-alike with no active medicine).
- Which treatment you get
- Chosen at random. Neither you nor the study team will know which treatment you get.
- Who can participate?
- We're looking for adults aged 18 and older with a diagnosis of psoriatic arthritis who have had symptoms for at least 3 months. Participants should have tried other medications without success. Think you might qualify? Apply to find out!
Where is the study taking place?
Palmetto Medical Plaza
Study details
- Sponsor
- Takeda
- Phase
- Phase 3: confirming it works in a large group, often against current treatment
- Dates
- March 2025 to January 2028 (expected)
- Size
- 1088 participants across all sites
- Healthy volunteers
- Only people with the condition
Study details are from ClinicalTrials.gov. The rest of this page is written by the study site for patients and may summarize or reword the registry record, which is the official text. A study listed on ClinicalTrials.gov has not necessarily been reviewed or approved by the U.S. government.
About NeoClinical Research
NeoClinical Research is a leading, multi-therapeutic clinical research center based in South Florida that bridges the gap between leading pharmaceutical companies and diverse patient populations.